NEW YORK, May 20, 2026, 09:18 EDT
- OACC last traded at $10.62, down about 0.8%, before Wednesday’s regular Nasdaq session.
- Fort Baker Capital disclosed a 5.1% passive stake in a May 15 SEC filing.
- The healthcare-focused SPAC has until Oct. 25, 2026, to complete a merger or seek more time.
Oaktree Acquisition Corp. III Life Sciences entered Wednesday’s premarket with its shares last trading at $10.62, leaving the healthcare blank-check company valued at about $261 million and still priced close to the cash value sitting behind the stock.
That matters because OACC is a special purpose acquisition company, or SPAC: a listed shell that raises cash, parks it in a trust account, then looks for a private company to merge with. Its March-quarter filing showed 19.2 million redeemable Class A shares with a redemption value of $10.60 each, only a shade below the latest share price.
The pressure point is time. OACC said it had until Oct. 25, 2026, to complete a business combination, the term SPACs use for their first merger or acquisition. If it seeks an extension, shareholders would get a chance to redeem, or cash out, which could cut the funds available for any deal.
There was no fresh merger announcement. The latest ownership signal came from Fort Baker Capital Management LP, which filed on May 15 that it and related reporting persons beneficially owned 1 million Class A shares, or 5.1% of the class, with shared voting and dispositive power. The filing said the shares were held in the ordinary course of business and not to change control.
OACC’s first-quarter numbers were SPAC-like rather than operating-company-like. It reported no operating revenue, $1.39 million of net income, and $1.85 million of interest earned on cash held in trust, offset by $456,538 of general and administrative expenses. The trust account stood at $203.4 million at March 31, while cash outside the trust was $1.28 million.
The company is looking in a crowded but reopening lane. Its annual filing says OACC is focused on healthcare and healthcare-related targets in North America, the UK and Western Europe, including biopharmaceuticals, medical devices, diagnostics and specialized healthcare services. It also says Oaktree had about $223 billion of assets under management at year-end 2025, and that Oaktree’s life-sciences platform had committed about $6.2 billion across 54 investments through Dec. 31.
Competitors for investor attention and private-company targets are already in the field. JATT II Acquisition priced a $60 million IPO in April with a biotechnology and life-sciences focus, while Blue Water Acquisition Corp. IV raised $125 million in March and said it was targeting biotechnology, healthcare and technology companies.
The wider market gives OACC some cover, but not a free pass. PwC said SPAC IPO issuance through the first quarter of 2026 reached its highest level since 2021, with 62 SPAC IPOs raising more than $11.8 billion, while pharma and life-sciences issuers accounted for seven of 22 traditional IPOs in the quarter.
The harder test is still deal quality. Baker McKenzie partner Michal Berkner told BioSpace last year that many de-SPACs “have not stood the test of time,” and said sponsors were effectively telling targets: “Let’s get ready.” That caution fits OACC’s situation: cash is useful, but the market will want a target that can survive public scrutiny. BioSpace
The risk paragraph is plain. OACC has not named a target, has no operating business of its own and flagged “substantial doubt” about its ability to continue as a going concern, meaning there is uncertainty over whether it can keep operating without a deal, more capital or an extension. A failed search could lead to liquidation of the trust and dissolution.
Until a transaction is announced, the stock is likely to be judged less on earnings than on trust value, filings and the narrowing calendar. That is a quiet trade, but not a low-stakes one.
